- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | eXoZymes Announces Graduation from Shell GameChanger Accelerator Powered by NLR Program | 449 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medicines... ► Artikel lesen | |
| Do | EXOZYMES INC. - 8-K, Current Report | 2 | SEC Filings | ||
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 10.04. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast | 751 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 31.03. | eXoZymes Provides Fourth Quarter and Full Year 2025 Update | 297 | ACCESS Newswire | Management to Host Conference Call Today at 5:30 PM Eastern LOS ANGELES, CA / ACCESS Newswire / March 31, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that... ► Artikel lesen | |
| 31.03. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 25.03. | eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 | 486 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 18.03. | Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability | 211 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 12.03. | eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium | 378 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 10.02. | eXoZymes unveils new website and branding to reflect pharma focus | 4 | Investing.com | ||
| 10.02. | With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation | 482 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / February 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes transforming abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 05.02. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.01. | eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run | 443 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways.The... ► Artikel lesen | |
| 16.12.25 | EXOZYMES INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.12.25 | eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion | 445 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 13.11.25 | eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today | 447 | ACCESS Newswire | Management to host Q3 2025 update at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced... ► Artikel lesen | |
| 13.11.25 | eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff | 443 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 10.11.25 | eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST | 397 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 10, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 30.10.25 | CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference | 405 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 29.10.25 | CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference | 419 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 29, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | Evotec-Aktie: Explodiert der Kurs jetzt Richtung 10€? | Nachdem der Kurs der Evotec-Aktie zuletzt deutlicher in Bewegung geraten ist, richtet sich der Blick nun auf die aktuellen Unternehmenszahlen und die operative Entwicklung. Der erwartungsgemäße Start... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | +4,83 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | +0,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| BIONTECH | 78,95 | -1,07 % | Aktien im Fokus - LPKF Laser: Party bald vorbei? - BioNTech, BVB, Elmos, Rheinmetall und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,510 | +8,55 % | Stifel Remains Bullish on Tango Therapeutics (TNGX) | ||
| INHIBRX BIOSCIENCES | 117,82 | +8,44 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| MODERNA | 43,090 | -5,01 % | JEFFERIES stuft Moderna auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Moderna auf "Hold" mit einem Kursziel von 45 US-Dollar belassen. Andrew Tsai bezog am Dienstag Stellung zur jüngsten Kursstärke... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,850 | -8,24 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| C4 THERAPEUTICS | 3,660 | +15,46 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,66 | +8,07 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| ENLIVEN THERAPEUTICS | 43,530 | +2,91 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Phase 1 data update for ELVN-001 expected mid-2026
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026
Strong balance... ► Artikel lesen | |
| STRYKER | 253,90 | +2,71 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,160 | +3,70 % | Tyra Biosciences GAAP EPS of -$0.64 | ||
| ADMA BIOLOGICS | 8,500 | +1,07 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen |
EXOZYMES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,880 Euro und damit +1,33 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.